Malaysia is rapidly gaining recognition as a promising hub for early-phase clinical research, particularly First-In-Human (FIH) studies. With a population of over 34 million, Malaysia’s ethnogenetic diversity provides a natural stratification for early-phase clinical trials, enabling researchers to evaluate drug responses across multiple genotypes within a single regulatory and operational framework. This diversity is especially valuable in pharmacogenomics, where interethnic variation in drug metabolism, efficacy, and safety can significantly shape trial outcomes.

Join our industry leader, Dr Voon Pei Jye, MD, MRCP (UK), MMed (NUS), Consultant Medical Oncologist, for an in-depth discussion on Malaysia’s clinical landscape and its readiness for FIH studies. Gain insights to the country’s regulatory landscape, application process, site networks and strategic considerations for conducting early-phase clinical development in this highly innovative market.

Speaker

Dr Voon Pei Jye, MD , MRCP (UK), MMed (NUS)
Consultant Medical Oncologist, Sarawak General Hospital, Malaysia